// App-Quantinova.ai

9099 : Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.

Researchers

Presenter

  • Allison M. Campbell

Principal Investigators

  • Roy S. Herbst

  • Scott N. Gettinger

  • Sarah B. Goldberg

  • Harriet M. Kluger

  • Anne C. Chiang

  • Rogerio Lilenbaum

  • Kurt A. Schalper

  • Ryan T. Sowell

  • Susan M. Kaech

  • Roy H. Decker

Medical Centers

  • Yale University School of Medicine, Department of Therapeutic Radiology, New Haven, CT

  • Yale University School of Medicine, New Haven, CT

  • Smilow Cancer Center, Yale New Haven Hospital, New Haven, CT

  • Yale Cancer Center, New Haven, CT

  • Yale University School of Medicine, New Haven, CT

  • Yale School of Medicine, Yale University, New Haven, CT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Prospective

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT02407171

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved